the initial public offering price to be $6.00 per share.Our common stock has been approved for listing on The NASDAQ Global Market under the symbol "NERV." We are an "emerging growth company" as defined by the Jumpstart Our Business Startups Act of 2012
forward-looking statements as a result of certain factors, including those discussed in the "Risk Factors" and other sections of this prospectus.Company OverviewWe are a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat
plan to develop and, if approved by the applicable regulatory authorities, commercialize our product candidates for the neuropsychiatric pharmaceutical market, which represents a significant
obtain additional funding to initiate human trials of MIN-301.3Table of ContentsOur StrategyOur strategy is to develop and, if approved by the applicable regulatory authorities, commercialize products with transformative potential addressing
and we cannot give any assurance that any of our product candidates will receive regulatory approval in a timely manner or at all, which is necessary before they can be commercialized.•Our clinical trials may fail to demonstrate adequately the safety and
efficacy of our product candidates, which could prevent or delay regulatory approval and commercialization, and also increase costs.•Results of earlier clinical trials may not be predictive of the results of
initial public offering price of $6.00 per share, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.We expect to use the net proceeds from this offering to fund part of the continued clinical development of
and development expenses to increase substantially in connection with our ongoing activities, particularly as we advance our product candidates into clinical trials.10Table of ContentsAs of March 31, 2014, we had cash and cash equivalents of $2.1 million.
development of one of our two lead product candidates, MIN-117, and to fund future clinical trials of our other product candidate, and to obtain regulatory approval for, and to commercialize, our
defense and enforcement of any patents or other intellectual property rights;•the effect of competing technological and market developments;•market acceptance of any approved product candidates;•the costs of acquiring, licensing or investing in additional businesses,
receive regulatory approval in a timely manner or at all, which is necessary before they can be commercialized.We have invested a significant portion of our efforts and financial resources in the licensing and development of our two lead product candidates:
currently hold no Investigational New Drug, or IND, approvals in the United States, and as a result do not intend to initiate human clinical trials of our product candidates (with the exception of
If the EMA, FDA or other comparable foreign regulatory authorities requires additional studies or data, we would incur increased costs and delays in the marketing approval
significance required by the EMA, FDA or other regulatory authorities for approval;•we may be unable to demonstrate that a product candidate's clinical and
collaboration, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.17Table of ContentsEven if we complete the necessary clinical trials, we cannot predict when or if we will obtain marketing approval to commercialize a product candidate
product candidates demonstrate safety and efficacy in clinical trials, the regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain marketing
approved products would further be subject to ongoing requirements imposed by the EMA, FDA, and other comparable foreign regulatory authorities governing the manufacture, quality control, further
fully understood, and additional scientific understanding and future drug or non-drug therapies may make our product candidates obsolete.Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.As product candidates are developed through pre-clinical to late stage clinical trials towards approval and commercialization, it is common that
treatments, including any similar generics, and biosimilars;•the timing of market introduction as well as alternative treatment;•our ability to offer our drugs for sale at competitive prices;•the clinical indications for which the product candidate is approved;•the convenience and ease of administration compared to alternative